efficacy of glp 1 receptor agonists Comparative effectiveness GLP-1 on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis Frontiers | GLP-1 Receptor Agonists:

GLP-1RAs are considered safe and reduce the risk of severe hypoglycemia in patients with chronic kidney disease

That being said the usual big 4 of nausea, vomiting, diarrhea and constipation lead the charge here as usual

Although the etiology of depression has not been fully elucidated, current scientific data emphasize the role of neurotrophic factors deficiencies, disturbed homeostasis between the nervous system and the immune and endocrine systems, as well as disturbances in brain energy metabolism and dysfunctions in the gut-brain axis as important factors in the pathogenesis of this neuropsychiatric disorder

While their cardiovascular and metabolic benefits are well established, emerging reports suggest potential dermatologic adverse effects, particularly nonscarring hair loss (NSHL)

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for type 2 diabetes management and now widely prescribed for chronic weight management

Consequently, researchers have devoted decades to studying incretins, postulating that incretin-based therapies could potentially reverse this diminished incretin effect and restore insulin secretion in patients with T2DM